載入...
Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS
Atypical hemolytic uremic syndrome (aHUS) is a genetic, life-threatening disease characterized by uncontrolled complement activation, systemic thrombotic microangiopathy (TMA), and vital organ damage. We evaluated the effect of terminal complement blockade with the anti-C5 monoclonal antibody eculiz...
Na minha lista:
| 發表在: | Blood |
|---|---|
| Main Authors: | , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
American Society of Hematology
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4449039/ https://ncbi.nlm.nih.gov/pubmed/25833956 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-09-600411 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|